Curative gene therapies for rare diseases

被引:16
|
作者
Maldonado, Rocio [1 ]
Jalil, Sami [1 ]
Wartiovaara, Kirmo [1 ,2 ]
机构
[1] Univ Helsinki, Stem Cells & Metab Res Program, Helsinki, Finland
[2] Helsinki Univ Hosp, Clin Genet, Helsinki, Finland
基金
芬兰科学院;
关键词
CRISPR-Cas9; Gene therapy; Genetic engineering; FETAL-HEMOGLOBIN; VISUAL RECOVERY; LYMPHOCYTES; CELLS; TRIAL; REPLACEMENT; DEFICIENCY; MECHANISMS; DELIVERY;
D O I
10.1007/s12687-020-00480-6
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Diseases caused by alterations in the DNA can be overcome by providing the cells or tissues with a functional copy of the mutated gene. The most common form of gene therapy implies adding an extra genetic unit into the cell. However, new genome engineering techniques also allow the modification or correction of the existing allele, providing new possibilities, especially for dominant diseases. Gene therapies have been tested for 30 years in thousands of clinical trials, but presently, we have only three authorised gene therapy products for the treatment of inherited diseases in European Union. Here, we describe the gene therapy alternatives already on the market in the European Union and expand the scope to some clinical trials. Additionally, we discuss the ethical and regulatory issues raised by the development of these new kinds of therapies.
引用
收藏
页码:267 / 276
页数:10
相关论文
共 50 条
  • [21] Developing gene and cell therapies for rare diseases: an opportunity for synergy between academia and industry
    Mavilio, F.
    GENE THERAPY, 2017, 24 (09) : 590 - 592
  • [22] Developing gene and cell therapies for rare diseases: an opportunity for synergy between academia and industry
    F Mavilio
    Gene Therapy, 2017, 24 : 590 - 592
  • [23] Ensuring patient access to gene therapies for rare diseases: Navigating reimbursement and coverage challenges
    Berry, Diane
    Hickey, Carolyn
    Kahlman, Lisa
    Long, James
    Markus, Christina
    Mccombs, Caitlin K.
    MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT, 2025, 33 (01)
  • [24] Exon Skipping Therapies for Rare Kidney Diseases
    Yamamura, Tomohiko
    Nozu, Kandai
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2025,
  • [25] DO NICE APPRAISAL PROCESSES REWARD INNOVATIVE AND CURATIVE THERAPIES? AN ASSESSMENT OF CURRENT AND POTENTIAL FUTURE TECHNOLOGY APPRAISALS FOR RARE DISEASES
    Miller, B.
    Wiesner, T.
    Dean, R.
    Maru, B.
    VALUE IN HEALTH, 2019, 22 : S250 - S250
  • [26] INVESTIGATING POTENTIAL MARKET FAILURE WITH CURATIVE CELL AND GENE THERAPIES
    Shaw, S.
    Wickstead, R.
    Woodhouse, F.
    Micallef, J.
    Rooney, Brooks C.
    VALUE IN HEALTH, 2020, 23 : S416 - S416
  • [27] Marketing authorisation for rare diseases: The European regulatory perspective using the example of gene and cell therapies
    SchueBler-Lenz, Martina
    Hofner, Benjamin
    ZEITSCHRIFT FUR EVIDENZ FORTBILDUNG UND QUALITAET IM GESUNDHEITSWESEN, 2024, 189 : 73 - 81
  • [28] EVOLUTION OF OBCS NECESSARY TO ACTIVATE VALUE WITHIN STEM CELL & GENE THERAPIES & RARE DISEASES
    Eslami, N.
    Garfield, S.
    Richardson, S.
    Negi, N.
    VALUE IN HEALTH, 2019, 22 : S863 - S863
  • [29] Does gene therapies clinical research in rare diseases reflects the competitivity of the country: Example of France
    Lutsyk, Karyna
    Gicquel, Tristan
    Cortial, Lucas
    Forget, Sylvain
    Braun, Serge
    Boyer, Pierre-Olivier
    Laugel, Vincent
    Blin, Olivier
    THERAPIE, 2024, 79 (05): : 505 - 518
  • [30] Gene and splicing therapies for neuromuscular diseases
    Benchaouir, Rachid
    Robin, Valerie
    Goyenvalle, Aurelie
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2015, 20 : 1190 - 1233